VaccinesXpert

The latest medical news on vaccination and vaccines
Online version

Welcome ,

Find hereafter the latest scientific publications from peer-reviewed journals focused on your area of expertise.

Vaccines for adults

Acceptability of a COVID-19 Vaccine among Adults in the United States: How Many People Would Get Vaccinated?

Vaccine 2020; aop:10.1016/j.vaccine.2020.08.043 | Reiter, Paul L. et al.

Coronavirus disease 2019 (COVID-19) was declared a pandemic in March 2020. Several prophylactic vaccines against COVID-19 are currently in development, yet little is known about people’s acceptability of a COVID-19 vaccine. We conducted an online...

Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico

The Journal of infectious diseases 2021; 223(7): 1241-9 | Bernard Beall et al.

After 7-valent pneumococcal conjugate vaccine introduction in the US in 2000, invasive pneumococcal disease (IPD) due to serotype 4 greatly decreased in children and adults. Starting in 2013, serotype 4 IPD incidence increased among adults >18 years...

One-year decline of poliovirus antibodies following fractional-dose inactivated poliovirus vaccine

The Journal of infectious diseases 2021; 223(7): 1214-21 | Ali Faisal Saleem et al.

Fractional dose (1/5 of full intramuscular dose) of inactivated poliovirus-vaccine administered intradermally (fIPV) is used as IPV dose-sparing strategy. We compared the rate of decline of poliovirus antibodies (PVA) in recipients of either two doses...

Future Vaccines and others

Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England

Vaccine 2020; aop:10.1016/j.vaccine.2020.08.007 | Beck, Ekkehard et al.

Invasive meningococcal disease (IMD), an uncommon but severe disease, affects mainly infants, young children and adolescents. Meningococcal B (4CMenB) and ACWY (MenACWY) vaccines targeting IMD-causing serogroups B and A, C, W and Y, respectively are available...

By requesting access to the "VaccinesXpert" service, I agree that GNM Healthcare Consulting France SAS may use the data acquired during my access request to provide me with weekly information related to its services in accordance with the Privacy Policy.
You have the right to access, rectify and delete your data, which you can exercise by sending your request to dpo@gnmhealthcare.com. You can exercise your right to object by requesting the deletion of your data at any time by clicking on the "Delete my data" link.